Skip to main content
Journal cover image

Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.

Publication ,  Journal Article
Joyce, LC; Baber, U; Claessen, BE; Sartori, S; Chandrasekhar, J; Cohen, DJ; Henry, TD; Ariti, C; Dangas, G; Faggioni, M; Aoi, S; Gibson, CM ...
Published in: JACC Cardiovasc Interv
May 27, 2019

OBJECTIVES: The aim of this study was to examine the association between dual-antiplatelet therapy (DAPT) cessation and cardiovascular risk after percutaneous coronary intervention in relation to age. BACKGROUND: Examination of outcomes by age after percutaneous coronary intervention is relevant given the aging population. METHODS: Two-year clinical outcomes, incidence, and effect of DAPT cessation on outcomes were compared by ages ≤55, 56 to 74, and ≥75 years from the PARIS (Patterns of Non-Adherence to Antiplatelet Regimens in Stented Patients) registry. DAPT cessation included physician-recommended discontinuation, interruption for surgery, and disruption (from noncompliance or bleeding). Clinical endpoints were major adverse cardiac events (MACE) (a composite of cardiac death, definite or probable stent thrombosis, spontaneous myocardial infarction, or clinically indicated target lesion revascularization), a secondary restrictive definition of MACE (MACE2) excluding target lesion revascularization, and bleeding. RESULTS: A total of 1,192 patients (24%) were ≤55 years, 2,869 (57%) were 56 to 74 years, and 957 (19%) were ≥75 years of age. Patients ≥75 years of age had higher DAPT cessation rates and increased risk for MACE2, death, cardiac death, and bleeding compared with younger patients. Discontinuation and interruption were not associated with increased cardiovascular risk across age groups, whereas disruption was associated with increased risk for MACE and MACE2 in younger patients but not in patients ≥75 years of age (p for trend <0.05). CONCLUSIONS: Nonadherence and outcomes vary by age, with patients ≥75 years having the highest DAPT cessation rates. We observed no association between outcomes and DAPT cessation in patients ≥75 years, whereas discontinuation was associated with lower MACE rates and disruption with increased MACE rates in patients <75 years.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

May 27, 2019

Volume

12

Issue

10

Start / End Page

983 / 992

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Stents
  • Risk Factors
  • Risk Assessment
  • Registries
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Joyce, L. C., Baber, U., Claessen, B. E., Sartori, S., Chandrasekhar, J., Cohen, D. J., … Mehran, R. (2019). Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv, 12(10), 983–992. https://doi.org/10.1016/j.jcin.2019.02.033
Joyce, Lauren C., Usman Baber, Bimmer E. Claessen, Samantha Sartori, Jaya Chandrasekhar, David J. Cohen, Timothy D. Henry, et al. “Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.JACC Cardiovasc Interv 12, no. 10 (May 27, 2019): 983–92. https://doi.org/10.1016/j.jcin.2019.02.033.
Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, et al. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 May 27;12(10):983–92.
Joyce, Lauren C., et al. “Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.JACC Cardiovasc Interv, vol. 12, no. 10, May 2019, pp. 983–92. Pubmed, doi:10.1016/j.jcin.2019.02.033.
Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Ariti C, Dangas G, Faggioni M, Aoi S, Gibson CM, Aquino M, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 May 27;12(10):983–992.
Journal cover image

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

May 27, 2019

Volume

12

Issue

10

Start / End Page

983 / 992

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Stents
  • Risk Factors
  • Risk Assessment
  • Registries
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Middle Aged